The paper, published in Clinical Infectious Diseases, analyzed EMR data from 2005 to 2010 for patients who used an outpatient primary care service at least once. The researchers estimated the proportion of the infected patients by identifying patient predictors of HCV positivity and then applying it to untested patients.
Of the study’s 209,076 patients, the researchers used the model to determine that 81.5 percent of HCV positive patients were unidentified using risk-based testing.
“Unidentified anti-HCV+ persons cannot receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease progression and mortality,” the researchers wrote in Clinical Infectious Diseases.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
